ANKRD22 and ductal breast carcinoma in situ: Intriguingly, Rebbeck et al. recently conducted a comprehensive transcriptomic study involving over 2,000 micro-dissected ductal lesions from 145 patients.108 In the study, they compared pure DCIS with concurrent DCIS which refer to DCIS with synchronous IDC and successfully identified some genes that were potentially responsible for DCIS progression, such as CAMK2N1, MNX1, ADCY5, HOXC11, and ANKRD22, which exhibited reduced expression in concurrent DCIS.